Patent intelligence · US
US 7514410
Hepatitis C therapies
Hepatitis C therapies
Patent details — US 7514410
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 7, 2009
- Expiration
- Apr 2, 2029
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Claims
- 42
- CPC classes
- A61K, A61K31/7056, A61K31/7064, A61K31/7068
Quick answer
US 7514410 (Hepatitis C therapies) is held by BioCryst Pharmaceuticals, Inc.. Status: granted. Granted Apr 7, 2009. Expires Apr 2, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 42
- CPC classes
- A61K, A61K31/7056, A61K31/7064, A61K31/7068, A61K38/212, A61K38/2292
More from BioCryst Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12162838
Human plasma kallikrein inhibitors
granted -
US 12121503
Antiviral treatments
granted -
US 12116346
Human plasma kallikrein inhibitors
granted -
US 12054492
Imidazole-containing inhibitors of ALK2 kinase
granted -
US 12043610
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted -
US 11975003
Methods and compositions for treatment of Zika virus infection
granted -
US 11866418
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted
Frequently asked questions
What is US patent 7514410?
US 7514410 (Hepatitis C therapies) is held by BioCryst Pharmaceuticals, Inc.. Status: granted. Granted Apr 7, 2009. Expires Apr 2, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7514410?
BioCryst Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 7514410 expire?
Our index shows an expiration date of Apr 2, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.